Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives, Diabetes & Metabolism, vol.39, issue.3, 2013. ,
DOI : 10.1016/j.diabet.2013.03.001
Liraglutide pour le traitement du diab??te de type 2, M??decine des Maladies M??taboliques, vol.4, issue.3, p.31325, 2010. ,
DOI : 10.1016/S1957-2557(10)70066-3
Biology of Incretins: GLP-1 and GIP, Gastroenterology, vol.132, issue.6, p.213157, 2007. ,
DOI : 10.1053/j.gastro.2007.03.054
Biochimie médicale, marqueurs actuels et perspectives, 2011. ,
Biochimie médicale. Marqueurs actuels et perspectives, 2011. ,
Le diabète de type 2. Le Moniteur Formation, 2014. ,
GLP-1 receptor agonists for type 2 diabetes. The Lancet. 10 juill, p.46, 2009. ,
An overview of the pharmacokinetics, efficacy and safety of liraglutide, Diabetes Research and Clinical Practice, vol.97, issue.1, p.2742, 2012. ,
DOI : 10.1016/j.diabres.2011.12.015
Le diabète de type 1. Le Moniteur Formation. 11 janv 2014, p.3014 ,
Acute necrotizing pancreatitis with liraglutide, THERAPIE. Ther J Société Fr Pharmacol Thérapeutique. nov, vol.67, issue.6, p.491554, 2012. ,
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. The Lancet. The Lancet. 12 janv 2013, p.89176 ,
Diabétologie clinique. 4e édition, 2011. ,
Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, BMJ. BMJ. 27 avr, vol.346, issue.7905, 2013. ,
Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows, BMJ, vol.346, issue.feb27 2, 2013. ,
DOI : 10.1136/bmj.f1304
Stratégie médicamenteuse du contrôle glycémique du diabète de type 2 Recommandations HAS/ANSM janvier 2013 ,
Les analyses biologiques. Le moniteur formation. 12 avr 2014 ,
Glucagon-like peptide 1 and appetite, Trends in Endocrinology & Metabolism, vol.24, issue.2, p.8591, 2013. ,
DOI : 10.1016/j.tem.2012.11.008
Endocrinologie Nutrition [Internet]. 6e édition Disponible sur: http://www.unitheque.com/Livre, VERNAZOBRES, 2011. ,
Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes, Diabetes & Metabolism, vol.34, issue.2, p.6572, 2008. ,
DOI : 10.1016/S1262-3636(08)73397-4
GLP-1: a new approach for type 2 diabetes therapy, Diabetes Research and Clinical Practice, vol.74, issue.2, p.1525, 2006. ,
DOI : 10.1016/S0168-8227(06)70021-3
Diab??te, pp.37-38452, 2013. ,
DOI : 10.1016/B978-2-294-01781-0.50147-3
Glucagon-like peptide 1 (GLP-1) and eating, Physiology & Behavior, vol.82, issue.1, p.179, 2004. ,
DOI : 10.1016/j.physbeh.2004.04.019
Prime suspect: the TCF7L2 gene and type 2 diabetes risk, Journal of Clinical Investigation, vol.117, issue.8, p.20779, 2007. ,
DOI : 10.1172/JCI33077
Incretin effect: GLP-1, GIP, DPP4, Diabetes Research and Clinical Practice, vol.93, p.326, 2011. ,
DOI : 10.1016/S0168-8227(11)70011-0
Incretin therapy and its effect on body weight in patients with diabetes, Primary Care Diabetes, vol.6, issue.3, p.18791, 2012. ,
DOI : 10.1016/j.pcd.2012.04.006
Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction, Primary Care Diabetes, vol.6, issue.1, p.416, 2012. ,
DOI : 10.1016/j.pcd.2011.09.002
Endocrine Diseases Atlas of nontumor pathology. First series. Fascicle 1. American Registry of Pathology (APR) and the Armed Forces Institute of Pathology (AFIP), 2002. ,
Endocrinologie et maladies métaboliques. 3e édition. Flammarion-Médecine Sciences, 2005. ,
Nutrition et maladies métaboliques. Flammarion-Médecine Sciences, 1999. ,
Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes, Journal of Clinical Investigation, vol.117, issue.8, p.215563, 2007. ,
DOI : 10.1172/JCI30706DS1
Prévalence du diabète traité pharmacologiquement et disparités territoriales en France en 2012, Disponible sur, pp.30-31493, 2014. ,
GLP-1 receptor agonists today, Diabetes Research and Clinical Practice, vol.93, issue.3, p.31727, 2011. ,
DOI : 10.1016/j.diabres.2011.01.004
Attempted suicide with liraglutide overdose did not induce hypoglycemia. Brief report, 2012. ,
Reduced incretin effect in Type 2 (noninsulin-dependent ) diabetes, Diabetologia. 1 janv, vol.29, issue.1, p.4652, 1986. ,
Atlas d'anatomie humaine, Masson et Icon Learning Systems, 2004. ,
The potential of incretin-based therapies in type 1 diabetes, Drug Discovery Today, vol.17, issue.1-2, p.8995, 2012. ,
DOI : 10.1016/j.drudis.2011.08.017
Endocrinologie Diabète Nutrition pour le praticien. SIMEP, 1994. ,
Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and ?? cell preservation, Progress in Biophysics and Molecular Biology, vol.107, issue.2, p.24856, 2011. ,
DOI : 10.1016/j.pbiomolbio.2011.07.010